Huawei's Ren Zhengfei, BYD's Wang Chuanfu, and Xiaomi's Lei Jun were among the leading tech executives that met Xi Jinping on ...
The U.S. IPO activity looks sluggish amid the holiday-shortened week. Nevertheless, the week prior saw Texas-based cybersecurity firm SailPoint price its upsized IPO of 60M shares at a public offering ...
The significance of Jack Ma’s appearance at this meeting cannot be overstated. Once seen as the face of China’s private ...
Xi Jinping meets China’s top tech leaders, signaling a new phase for business and innovation. What does this mean for the ...
An earlier version of this story misspelled the name of Smithfield Foods Inc. in its headline. Smithfield Foods Inc. is offering Wall Street a seat at the table for potential growth in its ...
Upcoming IPOs next week: From mainboard to SME, Check out the list of IPOs opening for subscription next week (Image: Freepik) Dr Agarwal Healthcare IPO GMP, Price Band, Issue Date: Dr. Agarwals ...
Denta Water & Infra Solutions IPO allotment status was declared today at around 4 PM, following a delay by the registrar. Denta Water & Infra IPO allotment was expected to be finalized by today ...
In the first big IPO of Trump 2.0, liquefied natural gas exporter Venture Global raised $1.75 billion last week by selling a 3% sliver of equity — 70 million shares at $25 a share. Investor ...
CTRL Group Limited raised $9.2 million through its IPO, with additional shares purchased by R.F. Lafferty & Co., Inc. CTRL Group Limited, a Hong Kong-based marketing and advertising services ...
Denta Water & Infra IPO Allotment Status Latest News Today (January 28): As per the GMP monitoring site investorgain.com, the current grey market premium for Denta Water IPO is Rs 76. Denta Water ...
Denta Water and Infra IPO Allotment Status: The initial public offering (IPO) of Denta Water and Infra Solutions Ltd has ended and received a stellar response. Denta Water and Infra IPO allotment ...
Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its GLP-1 receptor agonist. The New York-based company disclosed plans ...